ArticleMediators of inflammation2025
Electroacupuncture Attenuates Hepatic Ischemia-Reperfusion Injury by Modulating the Esr1/TAK1-JNK/p38 Signaling Pathway in Rats.
Article in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Electroacupuncture (EA) has demonstrated protective effects against hepatic ischemia-reperfusion injury (HIRI) in rat models. This study aimed to explore the underlying molecular mechanisms by which EA exerts its protective effects against HIRI. Gene expression microarray data from the Gene Expression Omnibus (GEO) database were analyzed to identify genes associated with HIRI, followed by differential expression analysis. Our results revealed that EA treatment significantly reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, as well as myeloperoxidase (MPO) activity in liver tissues. Histological analysis indicated decreased necrotic areas and apoptosis in EA-treated liver tissues. Molecular assessments demonstrated that EA downregulated Esr1 expression and inhibited the activation of the TAK1-JNK/p38 signaling pathway, thereby reducing hepatocyte apoptosis and inflammatory responses. These findings suggest that EA serves as a potent therapeutic approach to alleviate HIRI by targeting the Esr1/TAK1-JNK/p38 signaling pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.